AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

DBVT · NASDAQ · Biotechnology

DBV Technologies (ADR)

Develops an investigational skin patch for peanut allergy using epicutaneous immunotherapy.

$13.72

After-hours close+0.20 (+1.48%)

At close$13.52(−6.18%)

Something off on this page? Send us feedback.

Profile

DBV Technologies S.A.DBVTHealth Care

Develops the investigational Viaskin Peanut Patch, a skin-delivered immunotherapy candidate for peanut allergy. The business is concentrated on clinical development and a prospective U.S. launch, contingent on BLA submission and FDA review.

Develops Viaskin Peanut Patch, an investigational treatment candidate for peanut allergy based on epicutaneous immunotherapy, which delivers biologically active compounds through intact skin. The business is concentrated on this program rather than a marketed product portfolio, with clinical development focused on young children.

Operates from France with North American operations while building clinical, regulatory, and commercial capabilities for a prospective U.S. launch. Its near-term plan depends on completing the Biologics License Application package for FDA review; the therapies remain unapproved, and submission timing reflects FDA feedback on existing CMC and biostatistical datasets.

Company facts

CEODaniel Tassé

ListedOct 22, 2014

ExchangeNASDAQ

HeadquartersChâtillon, France

CountryFrance

Employees126

CIK0001613780

ISINUS23306J3095

Key statistics

Market cap$323.9M

EPS (ttm)−$1.98

P/E (ttm)−6.84

ROE-119.5%

P/B7.43

P/S81.15

Dividend yield—

Beta1.03vs XLV 0.29

Year to date −29.0% · Average volume (30d) 313.5K

Analysts

Price target, next 12 months$48.00+254.5%Median of 15 analysts · vs the Aug 28 close

ConsensusBuy10 of 15 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $13.54

High$51.00+276.7%

Median$48.00+254.5%

Low$40.00+195.4%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Dec 18, 2025	H.C. Wainwright	Target		$35	$40
Dec 17, 2025	Cantor Fitzgerald	Reiterate	Overweight	$42	$48
Dec 17, 2025	Guggenheim	Reiterate	Buy	$35	$51
Dec 15, 2025	H.C. Wainwright	Target		$16	$35
Dec 14, 2025	Cantor Fitzgerald	Target			$42

Earnings

EPS

Estimate−$0.16

ReportedDue Oct 28, 2026

Revenue

Estimate$664.0K

ReportedDue Oct 28, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Jul 16, 2026Q2 FY26	−$0.12	−$0.14	−14.4%	$778.2K	$800.8K	+2.9%	−1.08%
Apr 30, 2026Q1 FY26	−$0.14	−$0.56	−300.0%	$1.1M	$1.1M	−4.9%	−5.38%
Mar 27, 2026Q4 FY25	−$1.30	−$1.15	+11.5%	$1.5M	$574.6K	−60.5%	−2.20%
Oct 28, 2025Q3 FY25	−$1.45	−$1.20	+17.2%	$1.1M	$3.2M	+204.5%	−2.19%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$0	$0	$0	$0	$0	$0
Gross profit	$0	−$4.6M	−$4.3M	$0	$0	$0
Operating income	−$26.6M	−$43.1M	−$36.9M	−$45.1M	−$47.9M	−$51.3M
Net income	−$27.1M	−$42.4M	−$33.0M	−$44.8M	−$47.6M	−$50.4M
Diluted EPS	−$0.28	−$0.44	−$0.34	−$0.60	−$0.55	−$0.49
Gross margin	—	—	—	—	—	—
Operating margin	—	—	—	—	—	—

Fiscal years (4-quarter sums)FY21 $5.9M · FY22 −$1.3M · FY23 $13.4M · FY24 $3.0M · FY25 $0

Balance sheet, Jun 30, 2026Cash & short-term investments $174.9M · Total debt $21.0M · Total assets $223.2M · Shareholders' equity $160.4M

Dividends

No dividends on record.

Ownership

Institutions 88.53%Insiders —

Shares outstanding 23.92M · Float 14.54M · 60.8% free float

Insiders — filings are in the shares behind the receipt.

This listing is a depositary receipt and the Form 4 positions here are filed in the shares behind it, a different unit from the share count and in a ratio the filings never state, so no insider percentage is shown.

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Suvretta Capital Management, LLC	15.18M	9.90%	13G	Apr 11, 2025
Citadel Advisors LLC	9.16M	6.40%	13G	Apr 14, 2025
Bioimpact Capital LLC	5.21M	21.79%	13F	May 15, 2026
Vivo Capital, LLC	2.67M	11.15%	13F	May 20, 2026
Artisan Partners Limited Partnership	2.22M	9.28%	13F	May 13, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Jul 29, 2026	Pharis Mohideen	officer: Chief Medical Officer	−464	$2.70
Jan 29, 2026	Pharis Mohideen	officer: Chief Medical Officer	−534	$4.86
Dec 18, 2025	Bpifrance EPIC	other: Member of 10% owner group	−1,292,103	$4.19
Dec 17, 2025	Bpifrance EPIC	other: Member of 10% owner group	−2,076,990	$4.85
Nov 21, 2025	Pharis Mohideen	officer: Chief Medical Officer	−1,624	$2.77